Our Technology
Our Technology at CARA Yakhteh
At CARA Yakhteh, our technology platform is built around the precise engineering of autologous T cells to create highly targeted CAR T-cell therapies for hematologic malignancies. We combine advanced molecular biology, cell processing, and immunogenetics to deliver therapies that are personalized, potent, and scalable
🧬 Key Features of Our Platform:
- Antigen-Specific CAR Design: We develop chimeric antigen receptors tailored to tumor-associated markers such as CD19 and BCMA, enabling selective targeting of leukemia and multiple myeloma cells.
- Optimized T Cell Activation & Expansion: Our proprietary protocols ensure robust activation and proliferation of patient-derived T cells while preserving their cytotoxic function and persistence.
- Precision Genetic Modification: Using viral gene transfer technologies, we introduce CAR constructs with safety, minimizing off-target effects and insertional risks.
- Advanced Formulation & Cryopreservation: Final drug products are formulated, allowing for reliable transport and on-demand infusion at treatment centers.
- Integrated Manufacturing Workflow: From apheresis to infusion, our GMP-compliant process ensures quality, consistency, and scalability—tailored to the needs of regional healthcare systems.